The scientific data on anti-viral Covid pills still does not support that these medicines will be useful at the moment as it has been found that they need to be given earlier even before the diagnosis of the disease, Indian Council of Medical Research Director General Balram Bhargava said on Friday.
In a briefing on the present situation of Covid and new variant Omicron in the country, he said that it is very important to have low-intensity festivities and avoid non-essential travel and mass gatherings.
Joint Secretary, Health, Luv Agrawal, said that new Covid cases are being reported below 10,000 for the past 20 days. The case positivity for the last 1 week was 0.65 per cent. Currently, Kerala contributes 40.31 per cent to the total number of active cases in the country, he said.
India is administering Covid-19 vaccine doses at the highest rate in the world and the daily rate of doses administered is 4.8 times the rate of doses administered in the US and 12.5 times the rate of doses administered in the UK, he said.
On new Covid variant, he said that a total of 101 Omicron cases across 11 states have been reported so far.
"There is no evidence to suggest that vaccines are not effective against Omicron variant," he said, adding that it is likely that Omicron will outpace Delta variant where community transmission occurs as per a WHO report.
NITI Aayog's Member, Health, Dr V.K. Paul said: "A new phase of the Covid-19 pandemic is being experienced in Europe with a steep rise in cases."
About genome sequencing, he said that sequencing of every sample is not possible.
"It is a surveillance and pandemic assessment and tracking tool, not a diagnostic tool as of now."
--IANS
avr/vd
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)